AstraZeneca's trial flop raises a bigger question: Is its pipeline premium becoming more vulnerable?

For years, AstraZeneca has commanded one of the richest valuations among large European pharma companies on the assumption that it consistently delivers results.

You are being sent to the original publisher. FX Radar keeps this reference for market context and source discovery.